» Articles » PMID: 35699290

Changes in Intestinal Homeostasis and Immunity in a Cigarette Smoke- and LPS-induced Murine Model for COPD: the Lung-gut Axis

Abstract

Chronic obstructive pulmonary disease (COPD) is often associated with intestinal comorbidities. In this study, changes in intestinal homeostasis and immunity in a cigarette smoke (CS)- and lipopolysaccharide (LPS)-induced COPD model were investigated. Mice were exposed to cigarette smoke or air for 72 days, except , , and on which the mice were treated with saline or LPS via intratracheal instillation. Cigarette smoke exposure increased the airway inflammatory cell numbers, mucus production, and different inflammatory mediators, including C-reactive protein (CRP) and keratinocyte-derived chemokine (KC), in bronchoalveolar lavage (BAL) fluid and serum. LPS did not further impact airway inflammatory cell numbers or mucus production but decreased inflammatory mediator levels in BAL fluid. T helper (Th) 1 cells were enhanced in the spleen after cigarette smoke exposure; however, in combination with LPS, cigarette exposure caused an increase in Th1 and Th2 cells. Histomorphological changes were observed in the proximal small intestine after cigarette smoke exposure, and addition of LPS had no effect. Cigarette smoke activated the intestinal immune network for IgA production in the distal small intestine that was associated with increased fecal sIgA levels and enlargement of Peyer's patches. Cigarette smoke plus LPS decreased fecal sIgA levels and the size of Peyer's patches. In conclusion, cigarette smoke with or without LPS affects intestinal health as observed by changes in intestinal histomorphology and immune network for IgA production. Elevated systemic mediators might play a role in the lung-gut cross talk. These findings contribute to a better understanding of intestinal disorders related to COPD.

Citing Articles

Copper oxide nanoparticles exacerbate chronic obstructive pulmonary disease by activating the TXNIP-NLRP3 signaling pathway.

Kim W, Pak S, Lee S, Park S, Lim J, Kim D Part Fibre Toxicol. 2024; 21(1):46.

PMID: 39529109 PMC: 11552314. DOI: 10.1186/s12989-024-00608-3.


Identification of diagnostic biomarkers and immune cell profiles associated with COPD integrated bioinformatics and machine learning.

Zhu Z, Zeng Z, Song B, Chen H, Zeng H J Cell Mol Med. 2024; 28(18):e70107.

PMID: 39344484 PMC: 11440088. DOI: 10.1111/jcmm.70107.


Extract Protects Lipopolysaccharide-Induced Intestinal Inflammation in Mice via Promoting M2 Macrophage Polarization.

Wu H, Guo M, Zhao L, Zhang J, He J, Xu A Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204128 PMC: 11357656. DOI: 10.3390/ph17081023.


Cigarette smoke-induced dysbiosis: comparative analysis of lung and intestinal microbiomes in COPD mice and patients.

Laiman V, Chuang H, Lo Y, Yuan T, Chen Y, Heriyanto D Respir Res. 2024; 25(1):204.

PMID: 38730440 PMC: 11088139. DOI: 10.1186/s12931-024-02836-9.


Bidirectional association between pneumonia and intestinal infection: an analysis of the MIMIC-IV database.

Hou W, Zhu Y, Lai X, Yang Y Intern Emerg Med. 2024; 20(1):225-234.

PMID: 38717726 DOI: 10.1007/s11739-024-03631-6.


References
1.
Labarca G, Drake L, Horta G, Jantz M, Mehta H, Fernandez-Bussy S . Association between inflammatory bowel disease and chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulm Med. 2019; 19(1):186. PMC: 6819559. DOI: 10.1186/s12890-019-0963-y. View

2.
He Y, Wen Q, Yao F, Xu D, Huang Y, Wang J . Gut-lung axis: The microbial contributions and clinical implications. Crit Rev Microbiol. 2016; 43(1):81-95. DOI: 10.1080/1040841X.2016.1176988. View

3.
Ceelen J, Schols A, E M Kneppers A, Rosenbrand R, Drozdz M, van Hoof S . Altered protein turnover signaling and myogenesis during impaired recovery of inflammation-induced muscle atrophy in emphysematous mice. Sci Rep. 2018; 8(1):10761. PMC: 6050248. DOI: 10.1038/s41598-018-28579-4. View

4.
Bienenstock J, Befus D . Gut- and bronchus-associated lymphoid tissue. Am J Anat. 1984; 170(3):437-45. DOI: 10.1002/aja.1001700316. View

5.
Eldridge A, Betson T, Gama M, McAdam K . Variation in tobacco and mainstream smoke toxicant yields from selected commercial cigarette products. Regul Toxicol Pharmacol. 2015; 71(3):409-27. DOI: 10.1016/j.yrtph.2015.01.006. View